查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
細胞裂解市場增長、趨勢、COVID-19 的影響和預測 (2023-2028)
市場調查報告書
商品編碼
1190257

細胞裂解市場增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Cell Lysis Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，細胞裂解市場預計將以 8.5% 的複合年增長率增長。

COVID-19 大流行對呼吸系統的嚴重影響促使人們迫切需要新療法並增加藥物發現的數量，從而對細胞溶解市場產生積極影響。 已經進行了幾項研究以了解細胞溶解對冠狀病毒的影響。 例如，在 COVID-19 大流行高峰期，印度生物技術部 (DBT) 開展了一個項目，對樣本中的 1,000 個 SARS-CoV-2 基因組進行測序，以了解病毒在稻田中的進化行為。 在印度各地收集了樣本，以研究病毒的新突變以及它們如何改變疾病的症狀。 使用各種過程的研究活動的增加增加了對細胞裂解設備和試劑的需求。

由於研發支出的增加、製藥和生物製藥行業應用的擴大以及對個性化醫療的日益關注，預計該市場將會增長。 個體化醫療是遺傳學相關研究的最新趨勢之一，根據患者的具體需求提供量身定制的治療方案，對疾病的預防、診斷、預後和治療具有重要意義。我有。 根據 GLOBOCAN 的數據，2020 年全球將新增約 19,292,789 名癌症患者，約有 9,958,133 人死於癌症。 隨著傳染病和癌症的增加，用於研發的細胞樣本也在增加，這有望支持細胞裂解市場的增長。

在製造生物治療藥物和其他重組產品的下游過程中，細胞裂解和破碎方法的高采用率也推動了整個市場的增長。 此外，政府和私人組織增加對與生物技術過程和學術界相關的研發的投資預計將顯著推動市場。 然而，微尺度應用中的法規遵從性和機械過程問題是可能阻礙市場增長的一些因素。

細胞裂解市場的趨勢

預計未來幾年儀器將出現顯著增長

儀器是用於裂解細胞的工具或設備。 它們進一步分為超聲發生器、均質器、法壓機、微流化器等。 均質器和超聲儀等儀器主要用於細胞裂解/細胞分離，隨著超聲儀越來越多地用於細胞分離，需求量最大。

細胞裂解的最新進展使得在細胞裂解過程中出現了微流體裝置。 例如，根據《生物技術雜誌》2022 年 4 月發表的一項研究，微流體技術廣泛用於細胞裂解。 紅細胞的分離和裂解可用於診斷多種疾病，從而增加了對細胞裂解中微流體裝置的需求，並促進了市場增長。

隨著慢性病和傳染病數量的增加，研究實驗室和研究機構以及生物製藥和生物技術公司的需求增加，推動了整體醫藥需求。 例如，根據美國癌症協會2022年發布的報告數據，預計2022年美國將新增約1,918,030例癌症病例。 如此多的癌症患者表明需要研究和診斷這種□□疾病，這有望推動這一領域的增長。 用於細胞破碎和裂解的工具的商業可用性和可靠性也在推動這一領域的增長。

北美有望在預測期內主導市場

由於研發支出增加和慢性病發病率增加，北美在細胞溶解市場處於領先地位。 隨著 COVID-19 的興起，實驗室測試技術的增加有望加強細胞裂解市場的發展。 此外，研究 COVID-19 細胞反應和開發疫苗的科學家對細胞裂解系統和試劑產生了巨大需求。 因此，該地區越來越多的研究對市場產生了積極影響。

對用於治療癌症的細胞療法的需求不斷增加，預計也將促進細胞溶解市場的增長。 北美幾種疾病的患病率和發病率上升以及研發支出的增加正在推動所有生命科學學科對先進研發方案的需求。 根據藥物研究與製造商協會 (PhRMA) 的數據，到 2021 年，美國公司將進行全球一半以上的藥物研發。 同一份文件稱，2021 年美國在生物製藥研發方面的投資約為 1020 億美元。

因此，美國醫療保健基礎設施的持續增長和患者人數的增加為臨床實驗室的擴張提供了廣闊的機會，並將促進市場增長。

細胞裂解市場競爭分析

這個市場由國內外公司組成，競爭很低。 一些參與者包括 Thermo Fisher Scientific Inc.、Merck KGaA、F. Hoffmann-La Roche Ltd、Qiagen NV、Becton 和 Dickinson and Company。 這些公司正專注於新產品開發、收購和合作，以提高其市場地位。 隨著製藥和生物技術領域的進步，不少中小企業進入了這個市場。 相信在未來，這些公司將佔據研究市場的重要份額。 此外，由於新產品的推出，該市場的競爭正在加劇。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 研發費用增加
    • 在製藥和生物製藥行業的應用增加
    • 對個性化醫療越來越感興趣
  • 市場製約因素
    • 對法規的回應
    • 微尺度應用的機械過程問題
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（市場規模：百萬美元）

  • 按產品類型
    • 設備
      • 均質機
      • 離心機
      • 其他產品類型
    • 試劑
  • 按細胞類型
    • 哺乳動物細胞
    • 微生物細胞
    • 植物細胞
  • 最終用戶
    • 生物技術公司、生物製藥公司
    • 研究機構和學術機構
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation
    • Eppendorf AG
    • F. Hoffmann-La Roche Ltd
    • Labfreez Instruments Group Co. Ltd
    • Merck KGaA
    • Qsonica LLC
    • Takara Bio Inc.
    • Thermo Fisher Scientific Inc.
    • Cell Signaling Technology Inc.
    • Miltenyi Biotec
    • QIAGEN NV
    • Claremont BioSolutions LLC
    • Microfluidics International Corporation

第7章 市場機會與今後動向

簡介目錄
Product Code: 62783

The cell lysis market is expected to register a CAGR of 8.5% over the forecast period.

Severe respiratory consequences of the COVID-19 pandemic prompted an urgent need for novel therapies that increased the number of drug discoveries, thereby positively impacting the cell lysis market. Several research studies were conducted to understand the effect of cell lysis on coronavirus. For instance, during the peak of the COVID-19 pandemic, the Department of Biotechnology (DBT) in India undertook a project to sequence 1,000 SARS-CoV-2 genomes from samples to understand the evolving behavior of the virus. The samples were collected across India to study the emerging mutations in the virus and how they change the symptoms of the disease. The increase in research activities that used different processes increased the demand for cell lysis devices and reagents.

​The market is expected to grow due to increased expenditure on research and development, increasing application in the pharmaceutical and biopharmaceutical industries, and a rising focus on personalized medicine. Personalized medicine is one of the latest developments of gene-related studies that provide custom-tailored treatments as per the specific needs of patients, which has massive significance in disease prevention, diagnosis, prognosis, and therapeutics. According to the GLOBOCAN, in 2020, there were around 19,292,789 new cancer cases worldwide and about 9,958,133 deaths due to cancer. With the increase in the prevalence of infectious diseases and cancers, the use of cell samples for research and development of drugs also increases, which is expected to support the growth of the cell lysis market.

The high adoption of cell lysis and disruption methods during downstream processing to manufacture bio-therapeutics and other recombinant products further boosts the overall market growth. Furthermore, rising investments by governments and private organizations in R&D related to biotechnological processes and academics are expected to drive the market significantly. However, regulatory compliance and issues in the mechanical process in applying at the microscale level are some factors that might hinder market growth.

Cell Lysis Market Trends

Instruments are Expected to Witness Significant Growth in the Coming Years

Instruments are tools or devices used to lyse the cells. They are further categorized as sonicators, homogenizers, French press, microfluidizers, and others. Instruments like homogenizers and sonicators are used mostly for cell lysis/cell fractionation, and sonicators have the highest demand due to their increasing use in cell fractionation.

Recent advancements in cell lysis allowed the emergence of microfluidic devices in the cell lysis process. For instance, as per a study published by a Biotechnology Journal in April 2022, microfluidic technology is widely used for cell lysis. Separation and lysis of RBCs are helpful in the diagnosis of several diseases, which augments the demand for microfluidics in cell lysis, thus contributing to market growth.

With the rising number of chronic diseases and infectious diseases, there is a high demand in research laboratories and institutes and biopharmaceutical and biotechnology companies, which boosted the overall drug demand. For instance, as per the data from the American Cancer Society report published in 2022, around 1,918,030 new cancer cases were expected in United States in 2022. This high number of cancer cases indicates the need for research and diagnosis of the disease, which is expected to propel the growth of the segment . The commercial availability and reliability of tools used in cell disruption and lysis also boost the growth of this segment.

North America is Expected to Dominate the Market Over the Forecast Period

North America is spearheading the cell lysis market due to the increasing expenditure on research and development and increasing incidence of chronic diseases. With the rise in COVID-19, there was an increase in lab testing techniques, which was anticipated to intensify the progress of the cell lysis market. Furthermore, scientists researching COVID-19 cellular response and developing vaccines created a huge demand for cell lysis systems and reagents. Thus, increasing research in the region had a positive impact on the market.

The increasing demand for cell-based therapies for the treatment of cancer is also expected to augment the growth of the cell lysis market. The increasing prevalence and incidence of several diseases and rising research and development expenditure in North America trigger the need for an advanced research and development scenario across all life sciences sectors. According to the Pharmaceutical Research and Manufacturers Association (PhRMA), in 2021, US companies conducted over half the world's research and development in pharmaceuticals. The same source stated that approximately USD 102 billion was invested in biopharmaceutical R&D in United States in 2021. ​

Hence, the continuous growth of healthcare infrastructure in United States and the increase in the patient population provide wider opportunities for clinical laboratories to expand and help boost market growth.

Cell Lysis Market Competitive Analysis

The market studied is moderately competitive and consists of local and international companies. Some players include Thermo Fisher Scientific Inc., Merck KGaA, F. Hoffmann-La Roche Ltd, Qiagen NV, Becton, and Dickinson and Company, among others. These companies focus on novel product developments and acquisitions/collaborations to enhance their market positions. With advancements in the pharmaceutical and biotechnology sector, few small to mid-sized companies have entered the market. It is believed that these companies will hold a substantial share of the market studied in the future. Competition is also increasing due to new product launches in this market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Expenditure in Research and Development
    • 4.2.2 Increasing Application in the Pharmaceutical and Biopharmaceutical Industries
    • 4.2.3 Rising Focus on Personalized Medicine
  • 4.3 Market Restraints
    • 4.3.1 Regulatory Compliance
    • 4.3.2 Issues in Mechanical Process to Apply at the Microscale Level
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size - Value in USD million)

  • 5.1 By Type of Product
    • 5.1.1 Instruments
      • 5.1.1.1 Homogeniser
      • 5.1.1.2 Centrifugation
      • 5.1.1.3 Other Types of Products
    • 5.1.2 Reagents
  • 5.2 By Type of Cells
    • 5.2.1 Mammalian Cells
    • 5.2.2 Microbial Cells
    • 5.2.3 Plant Cells
  • 5.3 By End User
    • 5.3.1 Biotechnology or Biopharmaceutical Companies
    • 5.3.2 Research Laboratories and Academic Institutes
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 COMPANY PROFILES
    • 6.1.1 Becton, Dickinson and Company
    • 6.1.2 Bio-Rad Laboratories Inc.
    • 6.1.3 Danaher Corporation
    • 6.1.4 Eppendorf AG
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 Labfreez Instruments Group Co. Ltd
    • 6.1.7 Merck KGaA
    • 6.1.8 Qsonica LLC
    • 6.1.9 Takara Bio Inc.
    • 6.1.10 Thermo Fisher Scientific Inc.
    • 6.1.11 Cell Signaling Technology Inc.
    • 6.1.12 Miltenyi Biotec
    • 6.1.13 QIAGEN NV
    • 6.1.14 Claremont BioSolutions LLC
    • 6.1.15 Microfluidics International Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS